TIGIT and acute myeloid leukemia: Compared to the HIs, the percentage of NKG2D+ non-Vδ1/Vδ2 T cells was significantly decreased in the AML-DN group (median: 27.50% vs. 72.00%, p < 0.001), while the percentages of TIGIT+ non-Vδ1/Vδ2 T cells (median: 53.00% vs. 35.40%, p < 0.001) and Foxp3+ non-Vδ1/Vδ2 T cells (median: 5.87% vs. 0.99%, p < 0.001) were significantly increased.